IPECC - Instituto de Pesquisa Clínica de Campinas

Campinas 13060-080

3 studies enrolling now · 9 studies all time

What they study most

Acute Myocardial Infarction, COVID-19, Cardiovascular Risk, Chronic Kidney Disease, Heart Failure, Myocardial Infarction, SARS-CoV Infection

Studies at this site

• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
• Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) — Completed
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
• VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
• ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19 — Stopped early
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed